Fabre Kramer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FABRE KRAMER, and when can generic versions of FABRE KRAMER drugs launch?
FABRE KRAMER has one approved drug.
There is one US patent protecting FABRE KRAMER drugs.
There are three patent family members on FABRE KRAMER drugs in three countries.
Drugs and US Patents for Fabre Kramer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fabre Kramer | EXXUA | gepirone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021164-004 | Sep 22, 2023 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Fabre Kramer | EXXUA | gepirone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021164-001 | Sep 22, 2023 | DISCN | Yes | No | 7,538,116 | ⤷ Subscribe | ⤷ Subscribe | ||||
Fabre Kramer | EXXUA | gepirone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021164-004 | Sep 22, 2023 | DISCN | Yes | No | 7,538,116 | ⤷ Subscribe | ⤷ Subscribe | ||||
Fabre Kramer | EXXUA | gepirone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021164-002 | Sep 22, 2023 | DISCN | Yes | No | 7,538,116 | ⤷ Subscribe | ⤷ Subscribe | ||||
Fabre Kramer | EXXUA | gepirone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021164-003 | Sep 22, 2023 | DISCN | Yes | No | 7,538,116 | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Fabre Kramer Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 048128 | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2005053697 | ⤷ Subscribe |
European Patent Office | 1694332 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.